Human development

Digital Infuzion Welcomes Dr. Davyd Chung as Chief Growth Officer to Spearhead Strategic Expansion

Retrieved on: 
Lunedì, Maggio 6, 2024

ROCKVILLE, Md., May 6, 2024 /PRNewswire-PRWeb/ -- Joining the team on April 8, Dr. Davyd Chung brings over two decades of distinguished expertise in strategic growth and business development within the health sector.

Key Points: 
  • Digital Infuzion, a leader in health information technology solutions, is thrilled to announce the appointment of Dr. Davyd Chung as its new Chief Growth Officer.
  • Digital Infuzion is confident that Dr. Chung's strategic insights and leadership will propel the company towards new horizons of success and innovation in the health IT sector.
  • ROCKVILLE, Md., May 6, 2024 /PRNewswire-PRWeb/ -- Joining the team on April 8, Dr. Davyd Chung brings over two decades of distinguished expertise in strategic growth and business development within the health sector.
  • "Davyd's background in biomedical research and his proven track record in strategic growth are tremendous assets to us," said Hemant Virkar, CEO of Digital Infuzion.

Newark Native Mohamed Kamara Selected as 158th Draft Pick by the Miami Dolphins

Retrieved on: 
Mercoledì, Maggio 1, 2024

His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.

Key Points: 
  • His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.
  • At CSU, he exceeded expectations, earning the title of Mountain West Defensive Player of the Year.
  • On Saturday, April 27, 2024, his journey reached new heights when he was selected by the Miami Dolphins as the 158th pick in the NFL Draft, a testament to his skill, determination, and passion for the game.
  • "We are ecstatic to witness Mohamed Kamara's ascent in his football career," exclaimed Principal Terri Mitchell.

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Retrieved on: 
Giovedì, Aprile 11, 2024

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception.

Key Points: 
  • “Successful postcoital testing of Ovaprene: An investigational non- hormonal monthly vaginal contraceptive.” Contraception.
  • “Safety Testing of Ovaprene: an Investigational Non-Hormonal Monthly Vaginal Contraceptive.” Contraception.
  • Advance online publication, 110440. https://doi.org/10.1016/j.contraception.2024.110440
    “We are very pleased to have the postcoital test study results for our investigational, hormone-free intravaginal contraceptive Ovaprene published in a leading reproductive health journal,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • If successful, Daré expects the pivotal study to support marketing approvals of Ovaprene in the U.S. and other countries.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Giovedì, Marzo 28, 2024

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Sierra Metals Announces New Vice President, Health & Safety

Retrieved on: 
Lunedì, Marzo 4, 2024

Sierra Metals Inc. (TSX: SMT | OTCQX: SMTSF) (“Sierra Metals” or the “Company”) is pleased to announce the appointment of Mr. Astolfo Romero as Vice President, Health & Safety effective March 1, 2024 replacing Mr. Felix Guerra who is retiring after a very successful career in the mining industry.

Key Points: 
  • Sierra Metals Inc. (TSX: SMT | OTCQX: SMTSF) (“Sierra Metals” or the “Company”) is pleased to announce the appointment of Mr. Astolfo Romero as Vice President, Health & Safety effective March 1, 2024 replacing Mr. Felix Guerra who is retiring after a very successful career in the mining industry.
  • Ernesto Balarezo, CEO of Sierra Metals, commented, “We are very excited to have Astolfo join Sierra.
  • As a Postgraduate Teacher he received his Master's degree in Mining Management at GERENS and Pontificia Universidad Catolica del Peru.
  • Before joining Sierra, over the last 11 years, Mr. Romero served in multiple management positions in Volcan Compania Minera (Glencore) in areas such as Health & Safety, Operational Excellence, and Human Development.

The Foundation for the National Institutes of Health Launches First Public-Private Partnership for Early Detection of Preeclampsia

Retrieved on: 
Lunedì, Febbraio 12, 2024

The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.
  • Preeclampsia is a serious pregnancy-related hypertensive disorder that can lead to maternal and neonatal deaths and long-term negative health outcomes.
  • The disorder is becoming more prevalent in the United States, with women of color more likely to be affected and experience poor outcomes.
  • Currently, preeclampsia risk is determined early in pregnancy using a combination of maternal medical history and clinical risk factors.

HUMAN CAPABILITY INITIATIVE CONVENES POWERHOUSE LINE-UP OF SPEAKERS FOR EXPERT-LED PLATFORM IN RIYADH

Retrieved on: 
Mercoledì, Gennaio 31, 2024

150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative

Key Points: 
  • 150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative
    The breadth of high-level speakers and 6000+ global attendees demonstrate the collective impetus to unleash human capabilities potential through fostering intellectual dialogue in Riyadh.
  • RIYADH, Saudi Arabia, Jan. 31, 2024 /PRNewswire/ -- The Human Capability Initiative (HCI) is thrilled to announce key speakers for its forthcoming event taking place from the 28th – 29th February, 2024.
  • Bringing together luminaries from diverse sectors and backgrounds, these eminent industry leaders and experts will spearhead dynamic discussions centred around Human Capability Development (HCD) to prepare individuals for the challenges and opportunities of the future.
  • HCI's speaker line-up showcases the collective impetus across sectors to contribute to a sustainable global agenda that pioneers solutions for human capability development.

HUMAN CAPABILITY INITIATIVE CONVENES POWERHOUSE LINE-UP OF SPEAKERS FOR EXPERT-LED PLATFORM IN RIYADH

Retrieved on: 
Mercoledì, Gennaio 31, 2024

150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative

Key Points: 
  • 150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative
    The breadth of high-level speakers and 6000+ global attendees demonstrate the collective impetus to unleash human capabilities potential through fostering intellectual dialogue in Riyadh.
  • RIYADH, Saudi Arabia, Jan. 31, 2024 /PRNewswire/ -- The Human Capability Initiative (HCI) is thrilled to announce key speakers for its forthcoming event taking place from the 28th – 29th February, 2024.
  • Bringing together luminaries from diverse sectors and backgrounds, these eminent industry leaders and experts will spearhead dynamic discussions centred around Human Capability Development (HCD) to prepare individuals for the challenges and opportunities of the future.
  • HCI's speaker line-up showcases the collective impetus across sectors to contribute to a sustainable global agenda that pioneers solutions for human capability development.

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Retrieved on: 
Lunedì, Novembre 20, 2023

The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021.

Key Points: 
  • The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021.
  • “In 2020, Daré and Premier Research conducted a successful Phase 3 clinical study of XACIATO™ (clindamycin phosphate) vaginal gel 2% despite the challenges posed by a global pandemic.
  • “Premier Research is thrilled to renew this partnership and continue our successful work with Daré,” said Michael Arlotto, Ph.D., Chief Operating Officer of Premier Research.
  • “This partnership underscores our joint commitment to advancing women’s health by supporting efforts to include women in clinical research and bring novel products to market.

Tiny Love Emphasizes Its 6 Developmental Wonders by Helping Families Create Moments of Wonder for Their Little Ones

Retrieved on: 
Martedì, Novembre 28, 2023

FOXBOROUGH, Mass., Nov. 28, 2023 /PRNewswire/ -- The first year of a baby's life is filled with crucial cognitive milestones, from understanding language and exploring their surroundings to learning how to interact with loved ones. In line with this, Tiny Love, a pioneer in infant developmental products and the first to conceive and patent the Gymini — a play mat with attached arches — has been a global leader for over 30 years. With a mission to support families from newborns to toddlerhood, Tiny Love reinforced its 6 Developmental Wonders™ at an exclusive event in New York City. The brand leaned into the importance of sensory and cognitive play for today's infants in partnership with Erin O'Connor, a distinguished professor at New York University's Steinhardt School of Culture, Education, and Human Development, Chief of Education at Cooper, and co-host of the Parenting Understood podcast.

Key Points: 
  • With a mission to support families from newborns to toddlerhood, Tiny Love reinforced its 6 Developmental Wonders™ at an exclusive event in New York City.
  • "Tiny Love takes pride in creating products that are designed to stimulate your baby's senses, foster development, encourage bonding, and create moments of wonder throughout their first year of life," said Natalie Thompson, Tiny Love Brand Marketing Lead.
  • "Tiny Love shares my passion for early childhood development and it's wonderful to help educate parents about their 6 Developmental Wonders™."
  • To learn more about Tiny Love's 6 Developmental Wonders™ and how parents can create Moments of Wonder with their little ones, visit https://www.maxicosi.com/us-en/about-tiny-love .